FAST-ACTING INSULIN ASPART AT HIGH DOSES IN INDIVIDUALS WITH TYPE 2 DIABETES

被引：0
|
作者：
Bowering, K. [1 ]
Harvey, J. [2 ]
Kolaczynski, J. [3 ]
Snyder, J. [4 ]
Bode, B. [5 ]
机构：
[1] Univ Alberta, Div Endocrinol & Metab, Edmonton, AB, Canada
[2] Bangor Univ, Wrexham Acad Unit, Bangor, Gwynedd, Wales
[3] Novo Nordisk Inc, Clin Dev Diabet & Obes, Plainsboro, NJ USA
[4] Novo Nordisk Inc, Clin Dev Med & Regulatory Affairs, Plainsboro, NJ USA
[5] Atlanta Diabet Associates, Atlanta, GA USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
303
引用
收藏
页码：A133 / A133
页数：1
相关论文
共 50 条
  • [31] A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
    Lane, Wendy S.
    Favaro, Elena
    Rathor, Naveen
    Jang, Hak C.
    Kjaersgaard, Maiken I. S.
    Oviedo, Alejandra
    Rose, Ludger
    Senior, Peter
    Sesti, Giorgio
    Soto Gonzalez, Alfonso
    Franek, Edward
    DIABETES CARE, 2020, 43 (08) : 1710 - 1716
  • [32] Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
    Kildegaard, Jonas
    Buckley, Stephen T.
    Nielsen, Rasmus H.
    Povlsen, Gro K.
    Seested, Torben
    Ribel, Ulla
    Olsen, Helle B.
    Ludvigsen, Svend
    Jeppesen, Claus B.
    Refsgaard, Hanne H. F.
    Bendtsen, Kristian M.
    Kristensen, Niels R.
    Hostrup, Susanne
    Sturis, Jeppe
    PHARMACEUTICAL RESEARCH, 2019, 36 (03)
  • [33] Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide
    Jonas Kildegaard
    Stephen T. Buckley
    Rasmus H. Nielsen
    Gro K. Povlsen
    Torben Seested
    Ulla Ribel
    Helle B. Olsen
    Svend Ludvigsen
    Claus B. Jeppesen
    Hanne H. F. Refsgaard
    Kristian M. Bendtsen
    Niels R. Kristensen
    Susanne Hostrup
    Jeppe Sturis
    Pharmaceutical Research, 2019, 36
  • [34] Modeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes
    Schiavon, Michele
    Dalla Man, Chiara
    Cobelli, Claudio
    IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2018, 65 (09) : 2079 - 2086
  • [35] FAST-ACTING INSULIN ASPART COMPARED WITH RAPID-ACTING INSULIN ANALOGS IN THE ADVANCED HYBRID CLOSED-LOOP SYSTEM IN ADULTS WITH TYPE 1 DIABETES
    Amuedo, S.
    Herguido, N. Gros
    Bellido, V.
    Gallardo, G. Lopez
    Vinau, F. Losada
    Morales, A. Perez
    Moreno, A. Soto
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A104 - A105
  • [36] Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study
    Wendy Lane
    Mads Faurby
    Lise Lotte N. Husemoen
    Dmitriy L. Markovich
    Naveen Rathor
    Christophe De Block
    Diabetes Therapy, 2021, 12 : 3067 - 3077
  • [37] Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial
    Buse, John B.
    Carlson, Anders L.
    Komatsu, Mitsuhisa
    Mosenzon, Ofri
    Rose, Ludger
    Liang, Bo
    Buchholtz, Kristine
    Horio, Hiroshi
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2885 - 2893
  • [38] Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study
    Lane, Wendy
    Faurby, Mads
    Husemoen, Lise Lotte N.
    Markovich, Dmitriy L.
    Rathor, Naveen
    De Block, Christophe
    DIABETES THERAPY, 2021, 12 (12) : 3067 - 3077
  • [39] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial
    Komatsu, Mitsuhisa
    Ekelund, Magnus
    Horio, Hiroshi
    Kadowaki, Takashi
    ENDOCRINE JOURNAL, 2021, 68 (04) : 429 - 440
  • [40] Fast-Acting Insulin Aspart Use with the MiniMedTM 670G System
    Hsu, Liana
    Buckingham, Bruce
    Basina, Marina
    Ekhlaspour, Laya
    von Eyben, Rie
    Wang, Justin
    Lal, Rayhan A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (01) : 1 - 7
12345